Chemoattractant-induced release of elastase by tumor necrosis factor- primed human neutrophils: Auto-regulation by endogenous adenosine

Inflammation Research

Volumn 48, Issue 12, 1999, Pages 637-642

  Ottonello, L ^a   Amelotti, M ^a   Barbera, P ^a   Dapino, P ^a   Mancini, M ^a   Tortolina, G ^a   Dallegri, F ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Adenosine; Degranulation; Neutrophils; PDE type IV inhibitors; TNF

Indexed keywords

4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; ADENOSINE; ADENOSINE DEAMINASE; CHEMOATTRACTANT; CYCLIC AMP; ELASTASE; FORMYLMETHIONYLLEUCYLPHENYLALANINE; TUMOR NECROSIS FACTOR;

ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; DEGRANULATION; ENZYME RELEASE; HUMAN; HUMAN CELL; IMMUNOREGULATION; LEUKOCYTE ACTIVATION; MALE; NORMAL HUMAN; SIGNAL TRANSDUCTION;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; 4-(3-BUTOXY-4-METHOXYBENZYL)-2-IMIDAZOLIDINONE; ADENOSINE; ADENOSINE DEAMINASE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHEMOTACTIC FACTORS; COMPLEMENT C5A; CULTURE MEDIA; CYCLIC AMP; CYTOPLASMIC GRANULES; HOMEOSTASIS; HUMANS; INDICATORS AND REAGENTS; N-FORMYLMETHIONINE LEUCYL-PHENYLALANINE; NEUTROPHILS; PANCREATIC ELASTASE; PHOSPHODIESTERASE INHIBITORS; SULFONAMIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033400094     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000110050515     Document Type: Article

References (47)

1. [1] Ferrante A. Tumor necrosis factor alpha potentiates neutrophil antimicrobial activity: increased fungicidal activity against Torulopsis glabrata and Candida albicans and associated increases in oxygen radical production and lysosomal enzyme release. Infect Immun 1989; 57: 2115-22.
2. [2] Berkow RID, Wang D, Larrik JH, Dodson, RW, Howard TH. Enhancement of neutrophil superoxide by preincubation with recombinant human tumor necrosis factor. J Immunol 1987; 139: 3783-91.
3. [3] Brandt E, Petersen F, Flad HD. Recombinant tumor necrosis factor-α potentiates neutrophil degranulation in response to host defense cytokines neutrophil-activating peptide 2 and IL-8 by modulating intracellular cyclic AMP levels. J Immunol 1992; 149: 1356-64.
4. [4] Klebanoff SJ, Vadas MA, Harlan JM, Sparks HL, Gamble JR, Agosti JM, et al. Stimulation of neutrophils by tumor necrosis factor. J Immunol 1986; 136: 4220-5.
5. [5] Perussia B, Kobayashi M, Rossi MB, Anegon I, Trinchieri G. Immune interferon enhances functional properties of human granulocytes: role of Fc receptors and effect of lymphotoxin, tumor necrosis factor, and granulocyte-macrophage colony-stimulating factor. J Immunol 1987; 138: 765-74.
6. [6] Ottonello L, Morone P, Dapino P, Dallegri F. Monoclonal Lym-1 antibody-dependent lysis of B-lymphoblastoid tumor targets by human complement and cytokine-exposed mononuclear and neutro-philic polymorphonuclear leukocytes. Blood 1996; 87: 5171-8.
7. [7] Gamble JR, Harlan JM, Klebanoff SJ, Vadas MA. Stimulation of the adherence of neutrophils to umbelical vein endothelium by human recombinant tumor necrosis factor. Proc Natl Acad Sci 1985; 82: 8667-72.
8. [8] Baggiolini M, Waltz A, Kunkel SL. Neutrophil-activating peptide-1/interleukin-8, a novel cytokine that activates neutrophils. J Clin Invest 1989; 84: 1045-9.
9. [9] Albella SM, Smith CN, Ward PA. Adhesion molecules and inflammatory injury. FASEB J 1994; 8: 504-12.
10. [10] Nathan CF. Neutrophil activation on biological surfaces. Massive secretion of hydrogen peroxide in response to products of macrophages and lymphocytes. J Clin Invest 1987; 80: 1550-60.
11. [11] Ottonello L, Morone MP, Dapino P, Dallegri F. Tumour necrosis factor alpha-induced oxidative burst in neutrophils adherent to fibronectin: effects of cyclic AMP-elevating agents. Br J Haematol 1995; 91: 566-70.
12. [12] Malech HL, Gallin JI. Neutrophils in human diseases. N Engl J Med 1987; 317: 87-94.
13. [13] Styrt B. The role of phagocytes in non-infectious diseases. In: Klempner MS, Styrt B, Ho J, editors. Phagocytes and disease. London: Kluwer Academic, 1989: 145-69.
14. [14] Davies P, MacIntyre DE. Prostaglandins and inflammation. In: Gallin JI, Goldstein IM, Snyderman R, editors. Inflammation: Basic principles and clinical correlates. New York: Raven Press, 1992: 541-88.
15. [15] Cronstein BN. Adenosine, an endogenous anti-inflammatory agent. J Appl Physiol 1994; 76: 5-13.
16. [16] Cronstein BN, Kramer SB, Weissmann G, Hirschhorn R. Adenosine: a physiological modulator of superoxide anion generation by human neutrophils. J Exp Med 1983; 158: 1160-77.
17. [17] Cronstein BN, Levin RI, Belanoff J, Weissmann G, Hirschhorn R. Adenosine: an endogenous inhibitor of neutrophil-mediated injury to endothelial cells. J Clin Invest 1986; 78: 760-70.
18. 4 biosynthesis by endogenous adenosine in ligand-activated human neutrophils. J Exp Med 1997; 186: 1401-6.
19. [19] McGarrity ST, Stephenson AH, Webster RO. Regulation of human neutrophil functions by adenine nucleotides. J Immunol 1989; 142: 1986-94.
20. [20] Bazzoni G, Dejana E, Del Maschio A. Adrenergic modulation of human polymorphonuclear leukocyte activation. Potentiating effect of adenosine. Blood 1991; 77: 2042-8.
21. [21] Bouma MG, Jeunhomme TMMA, Boyle DL, Dentener MA, Voitenok NN, van den Wildenberg FAJM, et al. Adenosine inhibits neutrophil degranulation in activated human whole blood. J Immunol 1997; 158: 5400-8.
22. [22] Stewart AG, Harris T. Adenosine inhibits platelet-activating factor, but not tumour necrosis factor-α-induced priming of human neutrophils. Immunology 1993; 78: 152-8.
23. [23] Henson PM, Henson JE, Fittshen C, Bratton DL, Riches DWH. Degranulation and secretion by phagocytic cells. In: Gallin JL, Goldstein IM, Snyderman R, editors. Inflammation: Basic principles and clinical correlates. New York: Raven Press, 1992: 511-40.
24. [24] Ossana PJ, Test ST, Matheson NR, Regiani S, Weiss SJ. Oxidative regulation of neutrophil elastase-alpha-1-proteinase inhibitor interaction. J Clin Invest 1986; 77: 1939-51.
25. 2 inhibits apoptosis in human neutrophilic polymorphonuclear leukocytes. Role of intracellular cyclic AMP levels. Exp Hematol 1998.
26. [26] Bevilacqua M, Vago T, Baldi G, Renesto E, Dallegri F, Norbiato G. Nimesulide decreases superoxide production by inhibiting phosphodiesterase type IV. Eur J Pharmacol 1994; 268: 415-23.
27. [27] Wright CD, Kuipers PJ, Kobylarz-Singer D, Devall LJ, Klinkefus BA, Weishaar RE. Differential inhibition of human neutrophils function. Role of cyclic AMP-specific, cyclic GMP-insensitive phosphodiesterase. Biochem Pharmacol 1990; 40: 699-707.
28. [28] Ward A, Brodgen RN. Nimesulide: a preliminary review of its pharmacological properties and therapeutic efficacy in inflammation and pain states. Drugs 1988; 36: 732-53.
29. [29] Krammer GM. Adenosine: emerging role as an immunomodifying agent. J Lab Clin Med 1987; 110: 255-6.
30. [30] De La Harpe J, Nathan CF. Adenosine regulates the respiratory burst of cytokine-triggered human neutrophils adherent to biological surfaces. J Immunol 1989; 143: 596-602.
31. [31] Marone G, Thomas LT, Lichtenstein LM. The role of agonists that activate adenylate cyclase in the control of cAMP metabolism and enzyme release by human polymorphonuclear leukocytes. J Immunol 1980; 125: 2277-83.
32. [32] Brandolini L, Bertini R, Bizzarri C, Sergi R, Caselli G, Zhou D, Locati M, Sozzani S. IL-1β primes IL-8-activated human neutrophils for elastase release, phospholipase D activity, and calcium flux. J Leukoc Biol 1996; 59: 427-34.
33. [33] Taub DD, Anver M, Oppenheim JJ, Longo DL, Murphy WJ. T lymphocyte recruitment by interleukin-8 (IL-8). IL-8-induced degranulation of neutrophils releases potent chemoattractants for human T lymphocytes both in vitro and in vivo. J Clin Invest 1996; 97: 1931-41.
34. [34] Hanlon WA, Stolk J, Davies P, Humes JL, Munford R, Bonney RJ. rTNF alpha facilitates human polymorphonuclear leukocytes adherence to fibrinogen matrices with mobilization of specific and tertiary but not azurophilic granule markers. J Leukoc Biol 1991; 50: 43-8.
35. [35] Fittschen C, Sandhaus RA, Worthen GS, Henson PM. Bacterial lipopolysaccaride enhances chemoattractant-induced elastase secretion by human neutrophils. J Leukoc Biol 1988; 43: 547-56.
36. [36] Atkinson YH, Marasco WA, Lopez AF, Vadas MA. Recombinant human tumor necrosis factor-α. Regulation of N-Formyl-methionyl-leucil-phenylalanine receptor affinity and function on human neutrophils. J Clin Invest 1988; 81: 759-65.
37. [37] Tennenberg SD, Solomkin JS. Activation of neutrophils by cachectin/ tumor necrosis factor: priming of N-formyl-methionyl-leucyl-phenylalanine-induced oxidative responsiveness via receptor mobilization without degranulation. J Leukoc Biol 1990; 47: 217-23.
38. [38] McColl SR, Beauseigle D, Gilbert C, Naccache PH. Priming of the human neutrophil respiratory burst by granulocyte-macrophage colony-stimulating factor and tumor necrosis factor-α involves regulation at a post-cell surface receptor level. Enhancement of the effect of agents which directly activate G proteins. J Immunol 1990; 145: 3047-53.
39. 4, and platelet-activating factor. Dissociation from priming in human polymorphonuclear neutrophils. J Immunol 1991; 147: 3842-7.
40. [40] Cronstein BN, Kramer SB, Rosenstein ED, Korchak HM, Weissmann G, Hirschorn R. Occupancy of adenosine receptors raises cyclic AMP alone and in synergy with occupancy of chemoattractant receptors and inhibits membrane depolarization, Biochem J 1988; 15: 709-15.
41. [41] Sullivan GW, Holliday CT, Mandell GL. The specific type IV phosphodiesterase inhibitor rolipram combined with adenosine reduces tumor necrosis factor-α-primed neutrophil oxidative activity. Int J Immunopharmac 1995; 10: 793-803.
42. [42] Berne RM, Knabb RM, Ely SW, Rubio R. Adenosine in the local regulation of blood flow: a brief overview. Fed Proc 1982; 42: 3136-42.
43. [43] Cronstein BN. Methotrexate and its mechanism of action. Arthr Reumath 1996; 39: 1951-60.
44. [44] Gadangi P, Longaker M, Naime D, Levin RI, Recht PA, Montesinos MC, et al. The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. J Immunol 1996; 156: 1937-41.
45. [45] Morabito L, Montesinos MC, Schreibman DM, Balter L, Thompson LF, Resta R, et al. Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5′-nucleotidase-mediated conversion of adenine nucleotides. J Clin Invest 1998; 101: 295-300.
46. [46] Prabhakar U, Lipshutz D, O'Leary Bartus J, Slivjiak MJ, Smith III FJ, Lee JC, et al. Characterization of cAMP-dependent inhibition of LPS-induced TNFα production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor. Int J Immunopharmac 1994; 10: 805-16.
47. [47] Sekut L, Yarnall D, Stimpson SA, Noel LS, Bateman-Fite R, Clark RL, et al. Anti-inflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation. Clin Exp Immunol 1995; 100: 126-32.